Navigation Links
Juno Closes $134M Series B Round
Date:8/5/2014

SEATTLE, Aug. 5, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, Inc., a biotechnology company focused on bringing forward novel immunotherapies for cancer, today announced that it has closed its Series B round with $134M in new investment.

This latest round includes new investments by ten public mutual funds and healthcare-focused funds. All major prior investors participated as well. The company will use proceeds from the Series B round to continue advancing its chimeric antigen receptor (CAR) and T-cell receptor (TCR) pipeline, including CAR T-cell therapies directed against CD19 currently in phase 1/2 trials and solid tumor targets.

Juno announced the close of its $176M Series A in April. Combining the A and B rounds, Juno has raised more than $300M in less than 12 months.

"Juno continues to make significant progress in developing new therapies with the potential to radically change the outlook for patients battling cancer," said Hans Bishop, CEO of Juno. "We are delighted by the vote of confidence coming from new Series B investors and founding investors alike. Our funding puts us in a strong position to move forward with multiple CAR-T and TCR therapies and invest in the science that will support continued innovation with these game-changing technologies."

Leerink Partners LLC acted as exclusive financial advisor in this transaction.

Juno Therapeutics launched in December 2013 and was co-founded with financial support from ARCH Venture Partners and the Alaska Permanent Fund through a partnership managed by Crestline Investors.

About Juno

Juno is a clinical stage company that brings together innovative technologies from three of the world's leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center and Seattle Children's Research Institute – to advance a broad pipeline of potential curative immunotherapy treatments. Juno will build on breakthroughs in the design of novel immunotherapies to develop two distinct and complementary platforms – chimeric antigen receptors (CARs) and T-cell receptors (TCRs). The CAR technology is designed to target cell surface antigens that are expressed on cancer cells. In addition, the high-affinity TCR technology can also detect alterations in intracellular proteins present in tumor cells. These treatments have the potential to reduce longer-term toxicities associated with current chemotherapeutics. Juno's goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure. Each candidate has the potential to treat a variety of high-risk cancers.

Logo - http://photos.prnewswire.com/prnh/20140113/DC45426LOGO


'/>"/>
SOURCE Juno Therapeutics
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. CTD Holdings Closes $1.725 Million Private Placement
2. BioMedomics, Inc. Closes $690K Round of Financing
3. Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept
4. Z Trim Holdings Closes 2013 With Record Sales
5. Abeona Therapeutics Closes $750,000 in Seed Round to Develop Therapies for Children Suffering from Rare Sanfilippo Diseases
6. Fluential Closes $8 Million Series A Round to Drive Natural Language Product Development
7. Z Trim Holdings, Inc. Closes $1.4 Million Public Offering
8. Sensible Medical Innovations Closes on Financing Round Led by Boston Scientific Corporation
9. Terascala Closes Additional Funding Based on Strong OEM Sales and Release of ISB
10. VG Life Sciences, Inc. Closes on $2,235,000 from Private Fund
11. Pittsburgh Life Sciences Greenhouse Closes $315,000 In Half-Year Investments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... ... Last week, Callan Capital, an integrated wealth management firm specializing in asset ... Diego Life Science event at the Estancia La Jolla Resort and Spa. , Over ... Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former CEO ...
(Date:5/23/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... of Directors has approved the payment of a quarterly cash ... The cash dividend of $0.24 per share will ... of record as of the close of business on June ... of the Board of Directors and may be adjusted as ...
(Date:5/23/2016)... ... May 23, 2016 , ... ... focused on molecular nanotechnology, announced the winners for the 2015 Foresight Institute Feynman ... Feynman, are given in two categories, one for experiment and the other for ...
(Date:5/20/2016)... ... May 20, 2016 , ... Korean researchers say Manumycin A triggers ... a new way to treat the disease. Surviving Mesothelioma has just posted an article ... from several Korean institutions based their mesothelioma study on the fact the Manumycin A, ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
Breaking Biology News(10 mins):